Announcements

Schedule Of Analysts/Institutional Investor Meet/Con. Call

Transcript of Earnings Call held on 02-08-2022

22^nd Annual General Meeting – Proceedings.

Pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing copies of newspaper advertisement of unaudited financial results for the Quarter ended 30^th June 2022, published in Free Press Journal (English) and Pudhari (Marathi) in the prescribed format.

Presentation on Audited Financial Results for the quarter ended June 30, 2022.

Intimation of decision taken at the Board Meeting held on August 01, 2022- (i) approval of the Unaudited Financial Results (both Stand-alone and Consolidated) for the quarter ended June 30, 2022

Intimation about conference call for Indian and Overseas Investors to be held on Tuesday, August 02, 2022  to discuss about Unaudited financial results (Stand-alone and Consolidated) for the quarter ended June 30, 2022. Click here to see the invite

Intimation of Board Meeting to be held on Monday 01, August, 2022 inter alia, to consider and approve the unaudited Financial results (both Stand-alone  and Consolidated) for the quarter ended June 30, 2022.

Pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing the copy of the newspaper advertisement published in Free Press Journal (English) and Pudari (Marathi)

Pursuant to the provisions of Section 91 of the Act, the Register of Members and Share Transfer Books of the Company will remain closed from Wednesday, July 27, 2022 to, August 03, 2022 (both days inclusive) in connection with the AGM

Intimation about 22nd   Annual General Meeting will be on Wednesday, August 03, 2022 at 4.00 P.M. at the Corporate office of the Company situated at D-37/3, TTC, Industrial Area, MIDC, Turbhe, Navi Mumbai-400073.

Intimation that Trading Window shall remain closed for Directors, Designated Employees and Connected Persons with effect from July 01, 2022, and would be re-opened after 48 hours of date of announcement / declaration of Unaudited Financial Results for the quarter ended June 30, 2022

Transcript of Earnings Call held on 06-05-2022

Mr. Rahul Guha has taken charge as the Managing Director & Chief Executive Officer with effect from Wednesday, May 04, 2022. Mr. Rahul Guha will also function as the Managing Director & CEO of Nueclear Healthcare Limited, our wholly owned subsidiary. Mr. Dharmil Sheth, who was appointed as the Managing Director for the interim period to comply with the provisions of Sec. 203 (4) of the Companies Act, 2013, has demitted office effective from Wednesday, May 04, 2022 and will continue to be a Non-Executive, Non-Independent Director of the Company.Intimation

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to intimate that a conference call for the Indian and overseas analysts is arranged by our management to discuss the Company’s financial results for Quarter / Whole year ended March 31, 2022, on Friday, May 06, 2022 at 04.00 p.m. local time.Investorscallrevised

We wish to intimate that a conference call for the Indian and overseas analysts is arranged by our management to discuss the Company’s financial results for Quarter / Whole year ended March 31, 2022, on Friday, May 06, 2022 at 04.00 p.m. local time.

Mr. Rahul Guha, MD & CEO Designate, who will take charge tomorrow, the 4^th May 2022, and Mr. Sachin Salvi, Chief Financial Officer, will represent the Company .Investorscall

Presentation on Audited Financial Results for the quarter / whole year ended 31-03-2022InvestorsPresentation31032022

Intimation of decisions taken at the Board Meeting held on April 29, 2022, about approved the Audited Financial Results (Stand-alone and Consolidated) for the Financial Year ended March 31, 2022 and have also decided to declare an interim dividend at the rate of Rs. 15.00 (Rupees Fifteen only) per share (150% of the face value of Rs. 10/- each) for the financial year 2021-22. The Board has fixed, Thursday 12^th May 2022 as the record date for the purpose of determining the entitlement of shareholders for the interim dividend.

Intimation about Board Meeting scheduled to be held on Friday, April 29 ,2022 inter alia, to consider and approve the audited financial results (both Stand-alone and Consolidated) for the quarter / Financial year ended 31st March 2022.

Intimation that Trading Window shall remain closed for Directors, Designated Employees and Connected Persons with effect from April 01, 2022, and would be re-opened after 48 hours of date of announcement / declaration of Audited Financial Results for the Financial Year ended March 31, 2022

Pursuant to Regulation 30 and Regulation 31(8)(d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the Company has received approval from the National Stock Exchange of India and BSE Ltd. for reclassification of the outgoing Promoters and Promoter Group shareholders from Promoter category to to public category in accordance with the Regulation 31A (10) of SEBI (Listing and Disclosure requirements), Regulation 2015. https://investor.thyrocare.com/wp-content/uploads/2022/03/IntimationtoNSEandBSEforapprovalofreclassficationofshares.pdf

Presentation – Unaudited financial results for the quarter/nine months period ended 31-12-2021.https://investor.thyrocare.com/wp-content/uploads/2022/03/Presentationupdate.pdf

Intimation of decision taken at the Board Meeting held on February 12, 2022 to approved the unaudited Financial Results (Stand-alone and Consolidated) for the Quarter / Nine months ended December 31, 2021, and appointed Mr. Dharmil Sheth as Managing Director with effect from 12-02-2022 till the time Mr. Rahul Guha takes charge as MD and CEO.

The Board of Directors have, in order to comply with the provisions of Sub-Section 4 of Section 203 of the Companies Act, 2013, appointed Mr. Dharmil Sheth, presently a non-independent, non-executive director, to hold the position of Managing Director with effect from 12-02-2022 till the time Mr. Rahul Guha takes charge as MD and CEO.

Intimation about Board Meeting scheduled to be held on Saturday, February 12,2022 inter alia, to consider and approve the unaudited financial results (both Stand-alone and Consolidated) for the quarter / nine months ended 31st December 2021.

Press Release being issued by the Company for the appointment of Mr. Rahul Guha as the Managing Director & Chief Executive Officer of the Company. Enclosed press release:https://investor.thyrocare.com/wp-content/uploads/2022/02/Epic-Press-Release.docx-3.pdf

The Board of Directors of the Company, at their meeting held on Saturday, 05^th February, 2022, have approved appointment of  Mr. Rahul Guha as the Managing Director & Chief Executive Officer of the Company. He will be joining by May 2022.

The Board of Directors of the Company, at their meeting held on January 28, 2022, based on the recommendations of the Nomination & Remuneration Committee and Audit Committee, have appointed Mr. Sachin Salvi, presently working as Senior Vice President – Finance as the Chief Financial Officer of the Company with effect from January 28, 2022.